All In Biotech

Drug Trial Radar · NCT03067441

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

A Multicenter Open-Label Extension (OLE) Study To Assess The Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 MG

Last checked: Nov 20, 2026Latest source record: Mar 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,462

Actual

Start

Feb 3, 2017

Primary completion

Nov 5, 2019

Study completion Nov 5, 2019

Sponsor

Lead sponsor
Esperion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

Conditions

  • Hypercholesterolemia
  • Atherosclerotic Cardiovascular Disease

Interventions

  • bempedoic acidDrug

    bempedoic acid 180 mg tablets taken orally, once per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 82

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Jedidiah Clinical Research

    Tampa, Florida

  • L-MARC Research Center

    Louisville, Kentucky

  • Sentral Clinical Research Services

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.